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Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced
endothelial cell function
Cassin Kimmel Williams, Ji-Liang Li, Matilde Murga, Adrian L. Harris, and Giovanna Tosato
Delta-like 4 (Dll4), a membrane-bound li-
gand for Notch1 and Notch4, is selec-
tively expressed in the developing endo-
thelium and in some tumor endothelium,
and it is induced by vascular endothelial
growth factor (VEGF)–A and hypoxia.
Gene targeting studies have shown that
Dll4 is required for normal embryonic
vascular remodeling, but the mecha-
nisms underlying Dll4 regulatory func-
tions are currently not defined. In this
study, we generated primary human endo-
thelial cells that overexpress Dll4 protein
to study Dll4 function and mechanism of
action. Human umbilical vein endothelial
cells retrovirally transduced with Dll4 dis-
played reduced proliferative and migratory
responses selectively to VEGF-A. Expres-
sion of VEGF receptor-2, the principal
signaling receptor for VEGF-A in endothe-
lial cells, and coreceptor neuropilin-1 was
significantly decreased in Dll4-transduced
endothelial cells. Consistent with Dll4 sig-
naling through Notch, expression of
HEY2, one of the transcription factors
that mediates Notch function, was signifi-
cantly induced in Dll4-overexpressing en-
dothelial cells. The -secretase inhibitor
L-685458 significantly reconstituted endo-
thelial cell proliferation inhibited by immo-
bilized extracellular Dll4 and reconsti-
tuted VEGFR2 expression in Dll4-
overerexpressing endothelial cells. These
results identify the Notch ligand Dll4 as a
selective inhibitor of VEGF-A biologic ac-
tivities down-regulating 2 VEGF recep-
tors expressed on endothelial cells and
raise the possibility that Dll4 may be
exploited therapeutically to modulate an-
giogenesis. (Blood. 2006;107:931-939)
© 2006 by The American Society of Hematology
Introduction
Notch signaling plays a crucial role in cell fate determinations of a
variety of cell types during development and postnatally.1-5 Four
Notch receptors have been identified in mammals, Notch1,6
Notch2,7 Notch3,8 and Notch4,9 and 5 ligands, Jagged110 and
Jagged211 belonging to the Serrate family, and Delta1,12 Delta3,13
and Delta-like 4 (Dll4)14-16 belonging to the Delta family. Ligand
binding to Notch receptors triggers the proteolytic release of Notch
intracellular domain which translocates into the nucleus to form a
nuclear complex with the transcription factor RBP-J (also named
CSL and CBF1/Su(H)/Lag-1) and activates transcription of down-
stream target genes.17 In mammals, primary target genes of the
Notch-intracellular domain/RBP-J complex include the HES (Hairy/
Enhancer of Split)18,19 and HEY (HES-related with YRPW motif,
also named HERP, HES-related repressor protein)20-23 family of
genes, which act as transcription factors.
A number of observations indicate that the Notch signaling
pathway plays a critical role in vascular development and homeosta-
sis.24-26 In particular, the Notch1 and Notch4 genes are expressed in
endothelial cells within the embryonic vasculature,9,27-29 and mice
with targeted deletions of Notch1 alone or Notch1 plus Notch4
display severe defects in embryonic vascular remodeling with the
mutant embryos dying at approximately gestational day E9.5
(embryonic day 9.5).30 Expression of activated Notch4 in the
developing mouse vasculature also caused abnormal vessel struc-
ture and patterning, resulting in embryonic death at approximately
day E10.5.31 In addition, expression of active Notch4 in human
dermal microvascular endothelial cells inhibited endothelial cell
sprouting on collagen.32
Dll4 is the most recently identified Notch ligand14-16,33 and
was found to interact with Notch1 and Notch4.14,34 In situ
hybridization and immunocytochemistry studies showed that the
predominant site of Dll4 expression is the vasculature, particu-
larly the arteries, arterioles, and capillaries during develop-
ment,14,16,35 and small arteries, microvessels, and tumor vessels
in adult mice.35 This selectivity is unique among Notch li-
gands.30 Recently, mice with targeted deletions of the Dll4 gene
were generated, revealing characteristic vascular remodeling
defects similar to those previously observed in the Notch1
mutant and the Notch1 and Notch4 double mutant mice.30,35-37
Strikingly, mice with heterozygous deletions of the Dll4 gene
also failed to remodel the primary vascular plexus in the yolk
sack and died at the embryo stage, providing evidence for the
critical importance of Dll4 expression levels in vascular devel-
opment.30,35-37 The VEGF gene is the only other known example
of inactivation of a single allele resulting in marked vascular
defects and embryonic lethality in mice.38,39 In vitro, hypoxia
can induce the expression of both vascular endothelial growth
factor (VEGF) and Dll4 in endothelial cells.16,35,40,41
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Taking advantage of retroviral transduction, we have expressed
Dll4 in primary human endothelial cells to delineate Dll4 function
in these cells. We show that Dll4 inhibits expression of VEGF
receptor-2 (VEGFR2) and neuropilin-1 (NRP1) coreceptor and by
this mechanism likely modulates VEGF-A–induced endothelial
cell function.
Materials and methods
Constructs
The cDNA of human full-length Dll4 (GenBank no. AF253468) was cloned
from placental cDNA using as primers hDL4B sense, 5-GGATCCCATAT-
GGCGGCAGCGTCCCGTAGCGCCTC-3, and hDL4E antisense, 5-
GAATTCTTATACCTCCGTGGCAATGACACATTCATTC-3, followed by
TA cloning into pGEM-T easy vector (Promega, Southampton, United
Kingdom). Cloning accuracy was verified by DNA sequencing. Full-length
Dll4 was cut from the pGEM-T easy vector using BamHI and EcoRI
restriction enzymes and ligated into the retroviral plasmid LZRSpBMN-
linker-IRES-EGFP. Ligation sites were sequenced, and accuracy of inser-
tion was verified.
Cells, cell culture, and reagents
Human umbilical vein endothelial cells (HUVECs)42 were used at passages
3 to 7. The Phoenix amphotropic viral packaging cell line (Orbigen, San
Diego, CA) was grown in DMEM medium (Gibco-Invitrogen, Grand
Island, NY) supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Biofluids Rockville, MD) and 1.6 mM L-glutamine (Sigma Chemi-
cal, St Louis, MO). Recombinant human Dll4 was from R&D Systems
(Minneapolis, MN). The -secretase inhibitor L-685458 (Sigma Chemical
or Peptide Institute, Osaka, Japan), dissolved in dimethyl sulfoxide
(DMSO; Sigma Chemical), was used at final concentrations of 0.1 to
7.5 M.
Virus packaging and infection
Phoenix cells grown on 10-cm dishes to 50% confluency were transfected with
retroviral constructs using FuGENE6 (Roche Molecular Biochemicals, Indianap-
olis, IN) or Lipofectamine2000 (Invitrogen, Carlsbad, CA) for 24 hours. Fresh
HUVEC culture medium with 2 g/mL Puromycin (Sigma Chemical) was
added. After reaching confluency (24-48 hours), cells were washed and cultured
in Opti-MEM I (Gibco, Invitrogen) for 36 to 48 hours. The virus-containing
culture supernatant was filtered (0.4 m) and added with Polybrene (4 ng/mL;
Sigma Chemical) to 50% confluent HUVECs at passage 2.After 3 hours at 37°C,
cells were incubated in HUVEC culture medium for an additional 24 hours, at
which time cells were washed. Subsequently, the cells were maintained under
standard conditions.
RNA preparation and quantitative RT-PCR
Total RNA was extracted (Absolutely RNA Microprep Kit; Stratagene, La
Jolla, CA). Quantitative reverse transcriptase–polymerase chain reaction
(RT-PCR) was performed (One Step RT-PCR kit; Qiagen, Valencia, CA)
with SYBR Green PCR master mix (Applied Biosystem, Foster City, CA),
as described.43 The reaction was carried out in an Abi Prism 7900HT
sequence detection system (Applied Biosystems). Primers used included
GAPDH sense (5-GCCACCCAGAAGACTGTGGATGGC) and antisense
(5-CATGATGGCCATGAGGTCCACCAC), Dll4 sense (5-GACCACT-
TCGGCCACTATGT) and antisense (5-CCTGTCCACTTTCTTCTCGC),
HEY1 sense (5-AACTGTTGGTGGCCTGAATC) and antisense (5-
AATTCTTTGTGTTGCTGGGG), HEY2 sense (5-TTCAAGGC-
AGCTCGGTAACT) and antisense (5-GGGCATTTTACTTCCCCAAT),
ephrinB2 sense (5-GAAAATACCCCTCTCCTCAACT) and antisense
(5-CTTCGGAACCGAGGATGTTGTTC), Neuropilin-1 sense (5-
CAAGGCGAAGTCTTTTGAGG) and antisense (5-CACCTGTGAGCT-
GGAAGTCA), VEGFR1 sense (5-GCACCTTGGTTGTGGCTGAC) and
antisense (5-CGTGCTGCTGCTTCCTGGTCC), VEGFR2 sense (5-
GGAAATCATTATTCTAGTAGGCACGACG) and antisense (5-CCTGT-
GGATACACTTTCGCGATG), FGFR1 sense (5-GGAGGATCGAGCT-
CACTGTGG) and antisense (5-CGGAGAAGTAGGTGGTGTCAC),
VEGF-A sense (5-CCTTGCTGCTCTACCTCCAC) and antisense (5-
ATGTTGGACTCCTCAGTGGG), Notch1 sense (5-GCAACAGCTCCT
TCCACTTC) and antisense (5-GCCTCAGACACTTTGAAGCC),
Notch2 sense (5-CCCAATGGGCAAGAAGTCTA) and antisense (5-
CACAATGTGGTGGTGGGATA), Notch3 sense (5-TCTTGCTGCTG-
GTCATTCTC-3) and antisense (5-TGCCTCATCCTCTTCAGTTG-3),
and Notch4 sense (5-CACTGAGCCAAGGCATAGAC) and antisense
(5-ATCTCCACCTCACACCACTG). RT-PCR reactions were performed
at 50°C for 30 minutes, 94°C for 15 minutes, 35 cycles of 94°C for 1
minute, 60°C (58°C for Notch3 and 55°C for Notch1, Notch2, and Notch4)
for 1 minute, and 72°C for 1 minute, and 72°C for 10 minutes, followed by
a dissociation step of 15 minutes at 95°C, 15 minutes at 60°C, and 15
minutes at 95°C.
Cell-cycle analysis and flow cytometry
Cell-cycle analysis was carried out in HUVECs synchronized by 24 hours
in “starvation medium” consisting of M199 (Gibco-Invitrogen) with 2.5%
FBS (Biofluids), 25 g/mL porcine heparin (Sigma Chemical) or in
exponentially growing HUVECs. Cells were incubated in starvation
medium supplemented with 50 ng/mL VEGF-A (R&D Systems). Where
noted, cells were pulsed with 10 M 5-Bromo-2-deoxyuridine (BrdU;
Sigma Chemical) by incubation for 1 hour prior to harvest. At intervals
(0-72 hours), cells were detached with 0.05% Trypsin/ethylenediaminetet-
raacetic acid (EDTA) (Gibco, Invitrogen), washed, suspended in 0.5 to 1
mL cold 70% ethanol in PBS. After washing, incubation with 2 M
HCl/Triton X-100 for 30 minutes at room temperature, neutralization and
suspension in PBS containing 0.5% Tween-20 and 1% BSA, cells were
incubated with FITC-labeled mouse monoclonal anti-BrdU antibody (Bec-
ton Dickinson Immunocytometry Systems, San Jose, CA). For propidium
iodide (PI) incorporation, cells were suspended in PBS with 50 g/mL PI
(Sigma Chemical) and 100 U/mL Ribonuclease A (RNase; Sigma Chemi-
cal), incubated at 37°C for 30 minutes, and rinsed with PBS. At least 10 000
events were acquired, and results were analyzed with CellQuest (Becton
Dickinson, Franklin Lakes, NJ) and MODFIT LT software (Topsham, ME),
as described.44 For flow cytometric analysis of enhanced green fluorescent
protein (EGFP) expression, HUVECs were suspended in 0.5 mL PBS and
examined.43 Flow cytometric analysis of surface antigens was performed as
described.42 For VEGFR2 staining, we used mouse monoclonal anti-
VEGFR2 (ab9530; Abcam, Cambridge, MA) and Alexa594-labeled goat
antimouse antibody (Molecular Probes, Eugene, OR). Control staining was
with mouse IgG1 and Alexa594-labeled goat antimouse antibody. For
neuropilin-1 staining, we used PE-labeled mouse monoclonal anti–
BDCA-4 (human neuropilin-1) antibody (AD5-17F6 clone; Miltenyi Biotec
GmbK, Bergisch Gladbach, Germany) and for CD31 staining a PE-labeled
mouse monoclonal anti–human CD31 antibody (Pharmingen, BD Bio-
sciences, San Diego, CA). Data were collected using a fluorescence-
activated cell sorting (FACS) Calibur flow cytometer (Becton Dickinson)
and were analyzed using CELLQuest software (Becton Dickinson).
Immunocytochemistry
A rabbit immune serum against human Dll4 (named R3) was produced by
immunization with recombinant intracellular domain of Dll4 produced in
Escherichia coli. Human Dll4 intracellular domain was cloned into the
expression vector pET-28C-D4ICD, using primers: sense 5-GGATC-
CCATATGCGTCAG-CTGCGTCTTCGTCGTCCGG-3 and hDl4E anti-
sense (see “Constructs”). PCR product was cloned into pGEM-T easy
vector to produce the pGEM-T-D4ICD plasmid. The plasmid was then
digested with NdeI and EcoRI restriction enzymes, and the fragment was
inserted into pET-28C to produce the pET-28C-D4ICD expression vector.
The vector was transformed into BL21 Codon competent cells for
expression of recombinant protein, (MX3H6  10.D4ICD). Dll4 intracellu-
lar domain was purified from inclusion bodies and used for rabbit
immunization. Cytospin preparations of HUVECs (10-20 000 cells/slide,
38.2 g for 6 minutes) were fixed with acetone for 10 minutes at room
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temperature, washed with PBS over 20 minutes, blocked with 10% fetal
bovine serum in PBS, incubated with R3 rabbit antibody (1:300 dilution in
PBS containing 3% FBS, 1 hour at 37°C), washed in PBS over 20 minutes,
and then incubated with a goat antirabbit antibody labeled with horseradish-
peroxidase (DAKO, Carpinteria, CA) for 30 minutes at 37°C. After
washing, slides were incubated 30 minutes at room temperature in
3-amino-9-ethylcarbazol (AEC) substrate (21 mL 0.1 M Na acetate 79 mL
plus 0.1 M acetic acid plus 6 mL AEC, 100 L 30% H2O2) and
counterstained with Meyer hematoxylin for 5 to 10 minutes.
Western blotting and VEGF ELISA
Immunoblotting was performed as described.45 For Dll4 recognition, we
used rabbit R3 anti–human Dll4 antibody (dilution 1:250) with an
affinity-purified, peroxidase-linked, donkey IgG antirabbit antibody (Amer-
sham Biosciences, Piscataway, NJ); a mouse monoclonal anti–human/
mouse Dll4 (MAB1389, 1:500 dilution; R&D Systems) with a peroxidase-
linked donkey IgG antimouse antibody; or an affinity-purified goat
anti-Dll4 peptide antibody (C-20, 1:500 dilution; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) with a peroxidase-linked donkey anti–goat IgG
antibody (Santa Cruz Biotechnology). For identification of -actin, we used
a goat IgG anti-actin antibody (C11, 1:1000 dilution; Santa Cruz Biotechnol-
ogy) with a donkey anti–goat IgG HRP-conjugated (Santa Cruz Biotechnol-
ogy). Antibody detection was by chemiluminescence using enhanced
chemiluminescence (ECL; Amersham Pharmacia Biotech, Piscataway, NJ).
VEGF-A was measured by enzyme-linked immunosorbent assay (ELISA;
R&D Systems; lower limit of detection approximately 3 pg/mL).
Cell proliferation assay
HUVEC proliferation was measured as described.42 HUVECs were seeded
in triplicate in 96-well plates (2-4  103 cells/well in 0.2 mL RPMI 1640
culture medium supplemented with 18% heat-inactivated FBS [Biosource,
Camarillo, CA]) and 18 U/mL porcine heparin, with or without human
VEGF-A165 (3-24 ng/mL; R&D Systems) or human bFGF (3-28 ng/mL;
R&D Systems) and incubated for 3 days. HUVECs were also cultured onto
microtiter 96-well plates that were preincubated for 18 hours at 4°C with 50
L recombinant human Dll4 (1 g/mL in PBS or gelatin; R&D Systems).
When L-685458 was used, medium was replenished every 24 hours with
inhibitor or DMSO control. Proliferation was measured by 3H-thymidine
deoxyribose uptake (0.5 Ci [0.0185 MBq]/well, 25 Ci/mmol [925
GBq/mmol]; New England Nuclear, Boston, MA) during the last 18 to 22
hours of culture. Results are expressed as mean ( SEM) cpm/culture.
Matrigel cord formation assay
The in vitro matrigel assay was performed essentially as described.45
HUVECs were plated (40 000-75 000 cells) onto 24-well tissue culture
plates coated with 200 to 300 L solidified matrigel (an extract of the
Englebreth-Holm-Swarm tumor, Collaborative; BD Pharmingen, San Di-
ego, CA). After 16 to 18 hours of incubation, cells were photographed
(Retiga 1300 digital camera; Qimaging, Burnaby, BC, Canada) under
phase-contrast microscopy (Olympus 1  51 with a 10  0.25 NA PhL
lens; Olympus Optical, Melville, NY), and images were obtained with
IPLab for Windows software (Scanalytics, Fairfax, VA) imported into
Adobe Photoshop (Adobe Systems, San Jose, CA). Network formation was
measured by counting the number of cord angles/field (each field is defined
as the area visualized by a 4  magnification lens). Each experimental
condition was tested in 8 separate experiments.
Migration assay
Endothelial migration assays were performed using 0.2% gelatin-coated
polycarbonate filters (pore size 8 m) of transwells; Costar, Cambridge,
MA). HUVECs transduced with empty vector or Dll4 (5  105/well) were
placed in the upper chamber in migration medium (RPMI 1640 containing
0.5% BSA and 10 mM HEPES). The lower chamber contained migration
medium with or without 100 ng/mL VEGF-A or 100 ng/mL bFGF. After 16
to 20 hours of incubation at 37°C, viable cells in the lower chamber
were counted.
Statistical analysis
Group differences were evaluated by Student t test; P values less than .05
were considered significant.
Results
Up-regulation of Dll4 in primary human endothelial cells
We selected retrovirus-mediated transduction to overexpress Dll4
in primary human endothelial cells derived from the umbilical vein
(HUVECs) to achieve moderate levels of Dll4 expression. In
culture, HUVECs constitutively express low-level Dll4 mRNA
detected by RT-PCR.42 We found that approximately 90% of
HUVECs expressed enhanced green fluorescent protein (EGFP) on
day 3 after infection with the control retrovirus (Figure 1A). A
similar proportion of HUVECs (92%) expressed EGFP on day 3
after infection with Dll4 retrovirus (Figure 1A). When infection
efficiency fell below 60%, cells were FACS sorted for 100% EGFP
expression. The proportion of EGFP-positive cells decreased on the
average by approximately 15% over 7 to 10 days after infection. All
Figure 1. Dll4 expression in retrovirally transduced
primary human endothelial cells. (A) Flow cytometric
measurement of EGFP expression in HUVECs infected 3
days earlier with control retrovirus or Dll4 retrovirus.
Representative images from 8 independent infections.
(B) Levels of Dll4 expression in HUVECs 3 to 15 days
after transduction with control vector or Dll4 retrovirus
were evaluated by quantitative RT-PCR relative to GAPDH
expression. The results reflect the mean ( SEM) from
14 separate determinations from 8 infections. *P  .012.
(C) Dll4 and actin expression in HUVECs transduced with
control vector or Dll4 retrovirus evaluated by immunoblot-
ting with R3 rabbit anti-Dll4 antibody and reblotting with
goat anti–-actin antibody. (D-F) Immunocytochemical
analysis of Dll4 expression in HUVECs transduced with
Dll4 (F) or vector only (D) using rabbit anti-Dll4 antibod-
ies; control staining of Dll4-transduced HUVECs with
preimmune rabbit serum (E).
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results were obtained from 8 separate populations of cells in which
greater than 50% of cells were positive for EGFP.
By quantitative real-time PCR analysis, we found that Dll4
transcript levels were significantly higher in Dll4 cells than in
control cells. In 14 determinations from 8 separate infections,
levels of Dll4 expression normalized to GAPDH were 32-  5.9-
fold (mean  SEM) higher (P 	 .001) in Dll4 cells than in the
control cells (Figure 1B).
By immunoblotting, we found that antibody R3 we raised
against the intracellular domain of Dll4 identified a band
migrating at approximately 70 kDa in cell extracts from
Dll4-transduced cells but not in cell extracts from the control
cells (Figure 1C). The predicted molecular weight of full-length
Dll4 is calculated to be 75 kDa. This difference could not be
attributed to uneven loading as demonstrated by membrane
reblotting with antibodies directed against actin (Figure 1C).
Similar results showing Dll4 protein expression in Dll4 cells
were derived from membrane reblotting with a purified rat
monoclonal antibody raised against recombinant Dll4 (R&D
Systems) and with an affinity-purified goat polyclonal antibody
directed against a C-terminal peptide of Dll4 (Santa Cruz
Biotechnology) (not shown). We conclude that Dll4-transduced
HUVECs express Dll4 protein, whereas control HUVECs
express insufficient amounts of Dll4 protein to be detected by
Western blotting.
Up-regulation of Dll4 protein in transduced HUVECs was
confirmed by immunocytochemical staining of cytospin prepara-
tions. HUVECs infected with the Dll4 retrovirus were Dll4-
positive (brown staining) when immunostained by the R3 antibody
(Figure 1F). By contrast, HUVECs infected with the wild-type
vector (Figure 1D) were essentially negative. In addition, a
preimmune rabbit serum (from the same rabbit producing R3) did
not immunostain HUVECs transduced with Dll4 (Figure 1E).
Thus, these results demonstrate that primary human endothelial
cells can be transduced to overexpress Dll4.
Effects of Dll4 overexpression on endothelial cell proliferation
and cell-cycle progression
We examined the effects of Dll4 overexpression on HUVECs
growth in response to the proangiogenic factors vascular endothe-
lial growth factor (VEGF)–A and basic fibroblast growth factor
(bFGF). To best evaluate the effects of Dll4 overexpression rather
than clonal variation, we selected for functional experiments
HUVEC cultures in which similar proportions of cells were
EGFP-positive after infection with control and Dll4 retrovirus,
reflecting effective and comparable transduction levels. When
stimulated for 3 days in the presence of VEGF-A (25 ng/mL),
Dll4-transduced HUVECs consistently proliferated to a signifi-
cantly lower degree (P 	 .001) than the control cells (Figure 2A).
This difference was observed over a wide range of VEGF-A
concentrations (Figure 2B; representative experiment). Consistent
with this reduced proliferative capacity of Dll4-overexpressing
HUVECs, there were significantly fewer cells in VEGF-A (25
ng/mL)–supplemented cultures of Dll4-transduced HUVECs com-
pared with the control HUVECs (not shown). In a representative
experiment (of 4 performed), there were 115  103 Dll4-
transduced viable HUVECs as opposed to 216  103 control
HUVECs after 3-day incubation. In contrast to their reduced
proliferative response to VEGF-A, Dll4-transduced and control
HUVECs proliferated similarly in response to bFGF at varying
concentrations (Figure 2C; representative experiment). Thus, Dll4
overexpression in primary human endothelial cells is associated
with reduced proliferation in response to VEGF-A.
To characterize this reduced proliferative capacity of Dll4-
overexpressing HUVECs in response to VEGF-A, we examined
cell-cycle distribution during VEGF-A stimulation. First, the cells
were synchronized by culture for 24 hours under starvation
conditions (serum concentration in the culture medium was re-
duced 2.5%; ascorbate and ECGS omitted) and then stimulated
with VEGF-A (50 ng/mL) in starvation medium. Initially (0 time
point), the cell distribution in the different phases of the cell cycle
was similar in control and Dll4 HUVECs, reflecting a similar
proliferative capacity of these cells in the presence of endothelial
cell growth supplement, which contains bFGF and acidic FGF,
used for culture maintenance (Figure 3A, representative experi-
ment of 4 performed). However, at subsequent time points (24 and
48 hours), a clear difference in cell-cycle progression between
control cells and Dll4-overexpressing HUVECs was noted. In the
control cultures (vector), the percentage of cells in the G0/G1 phase
Figure 2. Effects of Dll4 expression on endothelial cell proliferation. (A)
HUVECs transduced 3 to 10 days earlier with either vector only or Dll4 (70%-90% of
cells expressing EGFP) were cultured for 72 hours in medium alone or medium
supplemented with VEGF-A (25 ng/mL); proliferation was measured by [3H] thymi-
dine deoxyribose uptake during the last 18 hours of culture. The results reflect the
means ( SEMs) from 5 separate experiments, each performed in triplicate cultures.
*P 	 .001. (B) Dose dependency of VEGF-A (3-24 ng/mL) induced HUVEC prolifera-
tion 3 to 10 days after transduction with vector only or Dll4 retrovirus. Cell proliferation
was measured as described in “Materials and methods”; the results reflect the means
( SDs) of triplicate cultures (representative of 4 determinations). (C) Analysis of
HUVEC proliferation in response to bFGF (3-28 ng/mL) 3 to 10 days after
transduction with vector alone or Dll4 retrovirus. Cell proliferation was measured as
described in “Materials and methods”; the results reflect the means ( SDs) of
triplicate determinations (representative of 4 determinations).
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of cell cycle fell from 84% (time 0) to 53% after 48-hour starvation
in the presence of VEGF-A, whereas the percentage of cells in the S
phase of the cell cycle correspondingly increased from 6.7% to
36%. Under the same culture conditions and testing, the percentage
of Dll4-transduced HUVECs (Dll4) in the G0/G1 phase of cell cycle
fluctuated between 83% and 90%, and the percentage of cells in S
phase fluctuated only between 5% and 6% (Figure 3A). These
experiments provided evidence that, after stimulation with VEGF-A,
HUVECs overexpressing Dll4 have a reduced capacity to enter S
phase compared with control cells.
Additionally, we confirmed this observation by measuring the
fraction of cells in the S phase of the cell cycle based on BrdU and
PI incorporation. Exponentially growing, unsynchronized HUVECs
were incubated for 72 hours in culture medium containing 2.5%
serum and 50 ng/mL VEGF. Under these restrictive culture
conditions, the proportion of BrdU-positive cells in the S phase of
the cell cycle decreased over 72 hours in both control and
Dll4-transduced HUVECs, despite the presence of VEGF-A, but
the reduction was greater in Dll4-overexpressing cells as compared
with control cells (Figure 3B).
Effects of Dll4 overexpression on endothelial cell migration
and matrix-dependent cord formation
These results provided evidence that Dll4-overexpressing endothe-
lial cells are defective in their ability to replicate in response to
VEGF-A. We examined whether this defect was limited to
VEGF-A–induced proliferation or extended to other nonmitogenic
functions of VEGF-A. In migration assays, VEGF-A (100 ng/mL)
and bFGF (100 ng/mL) promoted a significant response from
control HUVECs (Figure 4A). However, VEGF-A induced only
modest migration from Dll4-overexpressing HUVECs, which was
significantly (P  .021) reduced compared with the control
HUVECs. This difference was not associated with a more global
defect in cell migration, because Dll4-overexpressing HUVECs
and control HUVECs migrated to a similar degree (P  .74) in
response to bFGF (Figure 4A).
In additional analyses of nonmitogenic activities of VEGF-A,
we examined the ability of endothelial cells to undergo a morpho-
genic change into cordlike structures. When incubated on extracel-
lular matrices, such as collagen, fibrin, or matrigel (a mixture of the
extracellular matrix proteins laminin, collagen IV, heparan sulfate
proteoglycans, and entactin-nidogen), primary endothelial cells can
form a characteristic network of cordlike structures.43,45 With
HUVECs, matrigel-induced cord formation takes place over 6 to 16
Figure 4. Effects of Dll4 overexpression on endothelial cell migration and
extracellular matrix–dependent cord formation. (A) VEGF-A (100 ng/mL)– and
bFGF (100 ng/mL)–induced transwell migration of control and Dll4-overexpressing
HUVECs (5  105 cells/well) over 16 to 20 hours of incubation. The results reflect the
mean fold increase ( SEM) in cell migration compared with medium alone in 3
experiments performed in triplicate. (B) Representative images reflecting cord
formation by control and Dll4-overexpressing HUVECs (4-7.5  104 cells/well) plated
in complete culture medium on matrigel-coated wells (24-well plate) and incubated 16
to 18 hours. Phase-contrast microscopy (original magnification,  10). (C) Quantita-
tive analysis of matrigel-induced cord formation in control and Dll4-overexpressing
HUVECs. Cord formation was measured as a function of the number of cord angles
per visual field (phase-contrast microscopy, 4 magnification). The results represent
the mean ( SD) from 8 independent experiments. *P  .001.
Figure 3. Analysis of the effects of Dll4 overexpression on cell-cycle distribu-
tion. (A) HUVECs transduced with Dll4 or vector only (60%-90% of cells expressing
EGFP) were synchronized by 24-hour incubation in starvation medium supplemented
with 2.5% serum and then stimulated with VEGF-A (50 ng/mL) for 24 or 48 hours.
Cell-cycle distribution was evaluated by flow cytometric analysis of relative DNA
content, after cell fixation in cold 70% ethanol and incorporation of propidium iodide
(PI). The results, analyzed by MODFIT LT software, reflect the percentage of cells
found in the G0/G1, S, and G2/M phases of the cell cycle at time 0 (end of
synchronization), 24 and 48 hours after culture with VEGF-A. Representative
experiment of 4 performed. (B) Exponentially growing HUVECs transduced with
vector only or Dll4 (60%-90% of cells expressing EGFP) were cultured in serum-
reduced (2.5%) medium containing VEGF-A (50 ng/mL) for 24 to 72 hours. Cells were
pulsed with BrdU (10 M) over 1 hour prior to harvest. After fixation in 70% ethanol
and Triton-X 100 permeabilization, the cells were stained with FITC-labeled mouse
monoclonal anti-BrdU antibodies and subsequently allowed to incorporate PI.
Cell-cycle distribution was evaluated by flow cytometry. The results reflect the
percentage of cells in the S phase of cell cycle measured at time 0 (1 hour after
culture in serum-reduced medium), 24, 48, and 72 hours after incubation in
VEGF-A–supplemented serum-reduced culture medium.
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hours of incubation, does not require cell division, and is critically
dependent on endogenous VEGF-A and other factors.45-49 As
shown in a representative experiment (Figure 4B), the control
HUVECs formed the characteristic network of orderly branching
cordlike structures, Dll4-overexpressing HUVECs formed many
fewer such structures so that the network was often incomplete.
Quantitative analysis of network formation in 8 independent
experiments by measuring cord branching angles revealed that
Dll4-overexpressing HUVECs were significantly (P  .031) defec-
tive in their ability to form networks compared with control cells
(Figure 4C).
VEGFR2 and ephrinB2 modulation in endothelial cells
that overexpress Dll4
We examined whether the reduced capacity to assemble into
cordlike structures by Dll4-overexpressing cells might be attribut-
able to reduced expression of endogenous VEGF, which is required
for this morphogenic process. By quantitative RT-PCR analysis, we
found that levels of VEGF mRNA were similar (P  .82) in the
control- and Dll4-transduced HUVECs (Figure 5A). In addition,
culture supernatants from the control cells and Dll4-overexpressing
cells contained similar levels of VEGF (52 and 61 pg/mL,
respectively) after 20 hours of incubation on matrigel. This
provides evidence that Dll4 does not regulate VEGF expression in
HUVECs and suggests that reduced VEGF-A expression is not the
reason underlying defective matrigel-dependent network formation
by Dll4-overexpressing HUVECs.
On the basis of the observation that Dll4 overexpression is
associated with selectively reduced endothelial cell responses to
VEGF-A, we examined VEGFR2 expression in Dll4-overexpress-
ing HUVECs. It is known that VEGFR2 serves as the principal
signaling receptor for endothelial cell proliferation, migration,
survival, and angiogenesis induced by VEGF-A.50 By quantitative
RT-PCR analysis, we consistently (5 determinations) found that
VEGFR2 mRNA levels were significantly (P  .035) reduced in
Dll4-overexpressing HUVECs in comparison with control
HUVECs, whereas levels of VEGFR1 and FGFR1 mRNAs were
similar (P 
 .1; Figure 5A). Additionally, we consistently (7
determinations) found that RNA levels of NRP1, a coreceptor for
VEGF-A that enhances VEGF-A binding to VEGFR2,51 were
significantly (P  .003) reduced in Dll4-transduced cells compared
with control cells (Figure 5A). By flow cytometry, levels of surface
VEGFR2 and NRP1 expression were markedly reduced in Dll4-
overexpressing HUVECs compared with control HUVECs, whereas
levels of surface CD31 were similar (Figure 5B).
Notch expression in HUVECs and contribution of Notch
engagement to the phenotype of Dll4-transduced HUVECs
We looked for evidence of Notch expression in the HUVECs. By
RT-PCR, we determined that the vector-transduced HUVECs used
in the current experiment, express mRNA for the Notch receptors
Notch1, Notch2, and Notch4 but only low-level Notch3 mRNA
(Figure 6A). By quantitative RT-PCR analysis, we found that
HEY2 mRNA levels were consistently and significantly (P  .013)
increased in Dll4-transduced HUVECs compared with controls,
whereas HEY1 mRNA levels were similar (P  .2; Figure 6B).
Also, we found that ephrinB2 mRNA levels were significantly
(P  .019) higher in Dll4-overexpressing HUVECs than in the
control HUVECs, consistent with previous observations that
HEY1/HEY2-deficient mice do not express ephrinB2.52 Thus,
overexpression of Dll4 in HUVECs was associated with a signifi-
cantly enhanced expression of HEY2 and ephrinB2, consistent with
enhanced Notch signaling in these cells.
To more directly assess the contribution of Notch signaling to
the phenotype of Dll4-transduced HUVECs and distinguish it from
the potential contribution of reverse signaling by the intracellular
domain of Dll4, we used recombinant human Dll4 (rhDLL4),
which lacks the intracellular and transmembrane domains. We
found that rhDLL4 immobilized onto culture wells reduced HUVEC
proliferation in response to VEGF-A (Figure 6C). In addition, we
found that HUVECs cultured on plates coated with rhDLL4
showed decreased surface VEGFR2 expression compared with
HUVECs cultured on diluent-coated plates (Figure 6D). These
results demonstrate that the extracellular domain of Dll4 is
sufficient to inhibit endothelial cell proliferation in response to
VEGF-A and to reduce surface VEGFR2 expression. These effects
are similar to those induced by full-length Dll4, suggesting that the
intracellular and transmembrane domains of Dll4 are not required
for activity in the current system, and that Dll4 likely acts through
Notch rather than Dll4 signaling.
Proteolytic processing of Notch by -secretase is an essential
step after receptor activation.17 As a consequence, -secretase
inhibitors block activation of the Notch pathway. To further
establish that extracellular Dll4 inhibits VEGF-A–induced HUVEC
proliferation acting through Notch, we used the -secretase inhibi-
tor L-685458.53 As shown in Figure 6E, L-685458 specifically and
dose dependently reconstituted VEGF-A–induced HUVEC prolif-
eration reduced by rhDLL4. These results are consistent with Dll4
signaling through Notch receptors.
Figure 5. Regulation of VEGFR2 and NRP1 expression in Dll4-transduced
endothelial cells. (A) Quantitative RT-PCR analysis of VEGF-A, VEGFR1, VEGFR2,
FGFR1, and NRP1 expression in HUVECs transduced with vector only or Dll4. The
results reflect relative mRNA levels (normalized to GAPDH) in Dll4-transduced and
control HUVECs and are expressed as the fold mRNA change in Dll4 versus control
HUVECs. The results represent the mean ( SEM) from 4 to 9 independent
determinations. *P 	 .05. (B) Surface levels of CD31, VEGFR2, and NRP1 expres-
sion in vector-only (Vector) and Dll4-transduced (Dll4) HUVECs measured by flow
cytometry. Control reflects background surface fluorescence staining with appropri-
ate controls.
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We also tested the effects of the -secretase inhibitor L-685458
on VEGFR2 expression in control and Dll4-overexpressing
HUVECs (Figure 6F). When levels of VEGFR2 mRNA were
reduced by at least 5-fold in Dll4-transduced HUVECs compared
with vector-transduced HUVECs, L-685458 (2 M, 72-hour
incubation) significantly (P  .041) reconstituted VEGFR2 mRNA
levels in Dll4-overexpressing HUVECs compared with vector-
transduced HUVECs. Reconstitution of VEGFR2 expression was
more dependent on defined experimental conditions in Dll4-
overexpressing HUVECs compared with HUVECs induced by
rhDLL4, likely reflecting the complexities of the retroviral expres-
sion system. Together, these results provide evidence that Notch
signaling contributes to reduced expression of VEGFR2 and
reduced proliferation to VEGF-A in Dll4-transduced primary
endothelial cells.
Discussion
In this study, we have expressed Dll4 in primary human endothelial
cells by use of retroviral gene transduction and have identified Dll4
as a negative regulator of endothelial cell responses to VEGF-A.
We found that Dll4 down-regulates endothelial cell expression of
VEGFR2, which is the major mediator of the mitogenic, survival,
migration-promoting, and angiogenic activities of VEGF-A.50 We
also found that Dll4 down-regulates endothelial cell expression of
NRP1, which functions as a coreceptor for members of the
VEGF-A family, enhancing VEGFR2 activity.51 We and others
have shown that Dll4 RNA is induced by hypoxia or VEGF-A in
endothelial cells.16,35,41 Our current work extends these observa-
tions to demonstrate that Dll4 serves to dampen endothelial cell
responses to VEGF-A by reducing the expression of its principal
signaling receptor and coreceptor.
Previous studies have generally concluded that Notch activation
in endothelial cells serves to reduce angiogenic responses. Consti-
tutively active Notch4 inhibited the sprouting of primary human
dermal microvascular endothelial cells and reduced VEGF-induced
angiogenesis in the chick chorioallantoic membrane in vivo, in part
because of conformational changes in 1-integrins.32 Overexpres-
sion of active Notch1 or Notch4 inhibited the proliferation of
HUVECs, in part through repression of p21Cip1 expression.54
Constitutively active Notch1 inhibited the migration of mouse
embryonic endothelial cells.55 In addition, constitutively active
Notch1 or Notch4 reduced HUVEC proliferation in response to
VEGF but not bFGF.56 Consistent with Dll4 being a Notch1 and
Notch4 ligand,14,34 we have shown that the phenotype of endothe-
lial cells in which Dll4 is overexpressed bears similarity to the
phenotype of endothelial cells with active Notch1 or Notch4.
Recently, overexpression in HUVECs of Jagged1, another Notch
ligand expressed by endothelial cells, induced cell-cycle arrest and
reduced cell proliferation, similar to the effect of active Notch1 or
Notch4 under the same conditions.54 These observations would
suggest that in endothelial cells there is at least some functional
redundancy not only of Notch1 and Notch4 but also of Jagged1
and Dll4.
Overexpression of Dll4 in endothelial cells was accompanied
by a significant increase in the expression of the transcription factor
HEY2 with little or no change in the expression of HEY1.
Previously, active Notch1 and Notch4 were shown to up-regulate
expression of HEY1 in endothelial cells,56 indicating activation of
Figure 6. Expression of Notch receptors in endothelial
cells and Notch function in Dll4-transduced cells. (A)
mRNAs for Notch receptors 1 to 4 detected by RT-PCR in
HUVECs transduced with vector. (B) Quantitative RT-PCR
analysis of HEY1, HEY2, ephrinB2, and EphB2 expression in
control HUVECs transduced with vector only or Dll4-
overexpressing HUVECs. The results reflect relative mRNA
levels (normalized to GAPDH) and are expressed as the
mean ( SEM) fold mRNA change in Dll4 versus control
HUVECs from 2 to 11 separate determinations. *P	 .05. (C)
Effects of immobilized soluble recombinant human Dll4
(rhDLL4) on the proliferation of HUVECs. The endothelial
cells were cultured for 72 hours in the presence of VEGF-A
(25 ng/mL) on plates coated with rhDLL4 (1g/mL) or diluent
(0.1% BSA); proliferation was measured by 3H thymidine
deoxyribose uptake during the last 18 hours of culture. The
results reflect the means ( SDs) from triplicate cultures.
Representative experiment of 4 performed. *P	 .05. (D)
Surface levels of VEGFR2 expression in HUVECs cultured
for 48 hours onto rhDLL4-coated plates (1 g/mL) (rhDLL4)
or diluent-coated plates (gelatin) measured by flow cytom-
etry. Control reflects background surface fluorescence stain-
ing with appropriate controls. Representative of 2 performed.
(E) Effects of the -secretase inhibitor L-685458 (0.1-7.5M)
on the proliferation of HUVECs cultured with rhDLL4-coated
plates (1 g/mL); proliferation was measured by [3H] thymi-
dine deoxyribose uptake during the last 18 hours of culture.
The results reflect the means (SDs) from triplicate cultures.
Representative experiment of 4 performed. *P	 .01 (rhDLL4
with 4 M L-685458 inhibitor versus VEGF alone). (F)
Quantitative RT-PCR analysis of GAPDH and VEGFR2
expression in vector- and Dll4-transduced HUVECs after
72-hour culture with L-685458 (2 M) or diluent only (0.02%
DMSO). The results reflect relative mRNAlevels (normalized
to GAPDH) and are expressed as the mean ( SEM) fold
mRNA change in Dll4-transduced versus control HUVECs
from 4 separate experiments, in which levels of VEGFR2
expression in the absence of inhibitor were reduced by at
least5-fold inDll4-transducedcomparedwithcontrolHUVECs
(*P	 .05).
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different transcription factors by the ligand Dll4 and the active
Notch1 or Notch4 receptors. Because Dll4 has been reported to
also bind Notch2,15 which is expressed on HUVECs and other
endothelial cells,54 it is possible that active Notch2 may up-regulate
HEY2. If Notch receptors can activate different transcription
factors depending on the nature of the ligand and perhaps even the
degree and precise conditions of activation, this would provide a
basis for explanation of the complexities of the Notch system. It is
possible that the Dll4 intracellular domain may itself exert specific
signaling functions, consistent with what was previously hypoth-
esized for Dll1.57,58 However, we have demonstrated that down-
regulation of VEGFR2 expression and diminished proliferative
response to VEGF-A can be achieved through use of the extracellu-
lar domain of Dll4 alone. This suggests that the intracellular
domain of Dll4 is not necessary for these effects. Furthermore,
reduced VEGF-A–induced proliferation caused by extracellular
Dll4 can be overcome by the addition of the -secretase inhibitor
L-685458, providing strong evidence that Dll4 is signaling through
Notch receptors. In addition, an important contribution of Notch
signaling to the phenotype of Dll4-overexpressing cells is sup-
ported by the results presented here, showing that the inhibitor to
Notch signaling L-685458 significantly reconstituted VEGFR2
expression in Dll4-transduced endothelial cells.
We discovered here that overexpression of Dll4 is associated
with reduced expression of VEGFR2 and NRP1 in endothelial
cells, and this reduction is likely responsible for the abnormally
low proliferative and migratory responses to VEGF-A in Dll4-
overexpressing endothelial cells. Previously, constitutively active
Notch1 and Notch4 in endothelial cells were reported to down-
regulate VEGFR2 expression probably by decreasing VEGFR2
promoter activity,56 and overexpression of HEY1 in these cells
reduced levels of VEGFR2 mRNA.49 Our results confirm this link
between Notch signaling and down-regulation of VEGFR2 and
extend this observation in discovering that Dll4 also reduces NRP1
expression. The possibility that NRP1 expression may be regulated
by Notch signaling was raised by recent experiments showing that
the large arteries, which developed in mice with targeted deletions
of Notch1 or HEY1/HEY2, did not express NRP1.52
The role of NRP1 as a receptor for class-3 semaphorins, which
mediate neuronal guidance,59,60 and for several isoforms of VEGF-A,
enhancing VEGF-A activity,51 is well established. Recently, we and
others found that NRP1 regulates endothelial cell adhesion to
extracellular matrix and to other cells,43,61 indicating that NRP1 is
important in angiogenesis both as a modulator of VEGF-A activity
and a mediator of endothelial cell adhesion. This conclusion is
consistent with the marked vascular abnormalities developing in
mice with endothelial cell–targeted deletions of NRP162 and with
embryonic death associated with defects in the heart, vasculature,
and nervous system occurring in NRP1-deficient mice.63,64 By
down-regulating both VEGFR2 and NRP1 expression, Dll4 is
positioned to function as an endogenous inhibitor of angiogenesis.
The preferential expression of Dll4 in the developing arteries,
arterioles, and capillaries as opposed to veins,14,16 the arterial-
specific expression of HEY2,65 the loss of the CD44 and ephrinB2
arterial endothelial markers in the large arteries of Notch1 or
HEY1/HEY2-deficient mice,52 and the HEY2-induced expression
of many arterial endothelial cell markers in HUVECs65 have
suggested that the Dll4-Notch1/4-HEY1/2 pathway specifies arte-
rial endothelial fate during development.30 The observation herein
that HUVECs overexpressing Dll4 display increased levels of the
arterial marker ephrinB2 mRNA is consistent with this concept.
Dll4 expression in the tumor vascular endothelium and angiogenic
endothelium of the ovaries and its induction by exposure to
hypoxia and VEGF-A16,40,41 further suggest that Dll4 may also play
a role in postnatal endothelial cell differentiation processes during
angiogenesis.
Our identification of Dll4 as a repressor of endothelial cell
responses to VEGF-A, a principal proangiogenic factor, assigns a
previously unknown function to Dll4 and extends current concepts
of angiogenesis regulation. The challenge of future experiments
will be to evaluate the potential usefulness of Dll4 as an inhibitor of
angiogenesis for the treatment of cancer and other disorders
characterized by excessive angiogenesis.
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